Auris Medical

Auris Medical was founded in 2003 by Dr. Thomas Meyer with the mission of developing therapeutics that address important unmet medical needs in otology.

Auris Medical is currently running clinical trials for its first generation tinnitus drug, sensori-neural hearing loss and Meniere’s disease. A second generation of tinnitus drug is under preclinical development.

Clinical Trials — Recruiting

AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Condition: Hearing Loss
Intervention: Other: Placebo; Drug: AM-111 0.4 mg/ml; Drug: AM-111 0.8 mg/ml
Phase: Phase 3


AM-101 in the Treatment of Acute Tinnitus 3

Condition: Tinnitus
Intervention: Drug: AM-101; Drug: Placebo
Phase: Phase 3


Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Condition: Hearing Loss, Idiopathic Sudden Sensorineural
Intervention: Drug: AM-111 0.4 mg/ml; Drug: AM-111 0.8 mg/ml; Other: Placebo
Phase: Phase 3

Clinical Trials — Completed

AM-101 in the Treatment of Post-Acute Tinnitus 2

Condition: Tinnitus
Intervention: Drug: AM-101
Phase: Phase 3


Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus

Condition: Tinnitus
Intervention: Drug: AM-101
Phase: Phase 2


Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

Condition: Hearing Loss
Intervention: Drug: AM-111; Drug: placebo
Phase: Phase 2


AM-101 in the Treatment of Post-Acute Tinnitus 1

Condition: Tinnitus
Intervention: Drug: AM-101
Phase: Phase 3


AM-101 in the Treatment of Acute Tinnitus 2

Condition: Tinnitus
Intervention: Drug: AM-101; Drug: Placebo
Phase: Phase 3


Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus

Condition: Tinnitus
Intervention: Drug: AM-101 0.81 mg/mL; Drug: Placebo
Phase: Phase 2

RECENT NEWS ON AURIS MEDICAL

Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City

Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced that it will host a Key Opinion Leader event on Friday, June 16, 2017, at 8 am EDT in New York City. The event will focus on Auris Medical’s clinical-stage pipeline and feature a presentation by Elias Michaelides, MD, Associate Professor of Surgery, Otolaryngology and Director of the Hearing and Balance Program at the Yale School of Medicine.

COMPANY OVERVIEW

Auris Medical

Locations: Switzerland, Ireland, United States
Year Founded: 2003
CEO: Thomas Meyer (Ph.D.)